Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience - PubMed (original) (raw)
Randomized Controlled Trial
. 2014 Dec;28(12):3429-34.
doi: 10.1007/s00464-014-3617-4. Epub 2014 Jun 17.
Affiliations
- PMID: 24935203
- DOI: 10.1007/s00464-014-3617-4
Randomized Controlled Trial
Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience
Ashraf Abdelaziz et al. Surg Endosc. 2014 Dec.
Abstract
Background: Hepatocellular carcinoma (HCC) is a primary tumor of the liver with poor prognosis. For early stage HCC, treatment options include surgical resection, liver transplantation, and percutaneous ablation. Percutaneous ablative techniques (radiofrequency and microwave techniques) emerged as best therapeutic options for nonsurgical patients.
Aims: We aimed to determine the safety and efficacy of radiofrequency and microwave procedures for ablation of early stage HCC lesions and prospectively follow up our patients for survival analysis.
Patients and methods: One Hundred and 11 patients with early HCC are managed in our multidisciplinary clinic using either radiofrequency or microwave ablation. Patients are assessed for efficacy and safety. Complete ablation rate, local recurrence, and overall survival analysis are compared between both procedures.
Results: Radiofrequency ablation group (n = 45) and microwave ablation group (n = 66) were nearly comparable as regards the tumor and patients characteristics. Complete ablation was achieved in 94.2 and 96.1% of patients managed by radiofrequency and microwave ablation techniques, respectively (p value 0.6) with a low rate of minor complications (11.1 and 3.2, respectively) including subcapsular hematoma, thigh burn, abdominal wall skin burn, and pleural effusion. Ablation rates did not differ between ablated lesions ≤ 3 and 3-5 cm. A lower incidence of local recurrence was observed in microwave group (3.9 vs. 13.5% in radiofrequency group, p value 0.04). No difference between both groups as regards de novo lesions, portal vein thrombosis, and abdominal lymphadenopathy. The overall actuarial probability of survival was 91.6% at 1 year and 86.1% at 2 years with a higher survival rates noticed in microwave group but still without significant difference (p value 0.49).
Conclusion: Radiofrequency and microwave ablations led to safe and equivalent ablation and survival rates (with superiority for microwave ablation as regards the incidence of local recurrence).
Similar articles
- Percutaneous microwave ablation for HCV-related hepatocellular carcinoma: Efficacy, safety, and survival.
Darweesh SK, Gad AA. Darweesh SK, et al. Turk J Gastroenterol. 2019 May;30(5):445-453. doi: 10.5152/tjg.2019.17191. Turk J Gastroenterol. 2019. PMID: 31060999 Free PMC article. - [Efficacy of microwave ablation in treatment of hepatocellular carcinoma within the Milan criteria: a report of 696 cases].
Wang YM, Qian GJ, Xu Y, Wang N, Sheng YH. Wang YM, et al. Zhonghua Gan Zang Bing Za Zhi. 2017 May 20;25(5):344-348. doi: 10.3760/cma.j.issn.1007-3418.2017.05.007. Zhonghua Gan Zang Bing Za Zhi. 2017. PMID: 28763840 Chinese. - Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study.
Lu MD, Xu HX, Xie XY, Yin XY, Chen JW, Kuang M, Xu ZF, Liu GJ, Zheng YL. Lu MD, et al. J Gastroenterol. 2005 Nov;40(11):1054-60. doi: 10.1007/s00535-005-1671-3. J Gastroenterol. 2005. PMID: 16322950 - Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.
Majumdar A, Roccarina D, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Majumdar A, et al. Cochrane Database Syst Rev. 2017 Mar 28;3(3):CD011650. doi: 10.1002/14651858.CD011650.pub2. Cochrane Database Syst Rev. 2017. PMID: 28351116 Free PMC article. Review. - Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma.
Weis S, Franke A, Mössner J, Jakobsen JC, Schoppmeyer K. Weis S, et al. Cochrane Database Syst Rev. 2013 Dec 19;(12):CD003046. doi: 10.1002/14651858.CD003046.pub3. Cochrane Database Syst Rev. 2013. PMID: 24357457 Review.
Cited by
- Microwave ablation compared with radiofrequency ablation for treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis.
Glassberg MB, Ghosh S, Clymer JW, Qadeer RA, Ferko NC, Sadeghirad B, Wright GW, Amaral JF. Glassberg MB, et al. Onco Targets Ther. 2019 Aug 13;12:6407-6438. doi: 10.2147/OTT.S204340. eCollection 2019. Onco Targets Ther. 2019. PMID: 31496742 Free PMC article. - Microwave versus radiofrequency ablation for the treatment of liver malignancies: a randomized controlled phase 2 trial.
Radosevic A, Quesada R, Serlavos C, Sánchez J, Zugazaga A, Sierra A, Coll S, Busto M, Aguilar G, Flores D, Arce J, Maiques JM, Garcia-Retortillo M, Carrion JA, Visa L, Villamonte M, Pueyo E, Berjano E, Trujillo M, Sánchez-Velázquez P, Grande L, Burdio F. Radosevic A, et al. Sci Rep. 2022 Jan 10;12(1):316. doi: 10.1038/s41598-021-03802-x. Sci Rep. 2022. PMID: 35013377 Free PMC article. Clinical Trial. - Recent Advances in the Image-Guided Tumor Ablation of Liver Malignancies: Radiofrequency Ablation with Multiple Electrodes, Real-Time Multimodality Fusion Imaging, and New Energy Sources.
Lee DH, Lee JM. Lee DH, et al. Korean J Radiol. 2018 Jul-Aug;19(4):545-559. doi: 10.3348/kjr.2018.19.4.545. Epub 2018 Jun 14. Korean J Radiol. 2018. PMID: 29962861 Free PMC article. Review. - Local ablative treatments for hepatocellular carcinoma: An updated review.
Facciorusso A, Serviddio G, Muscatiello N. Facciorusso A, et al. World J Gastrointest Pharmacol Ther. 2016 Nov 6;7(4):477-489. doi: 10.4292/wjgpt.v7.i4.477. World J Gastrointest Pharmacol Ther. 2016. PMID: 27867681 Free PMC article. Review. - Microwave Ablation Versus Radiofrequency Ablation for Treatment of Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials.
Facciorusso A, Abd El Aziz MA, Tartaglia N, Ramai D, Mohan BP, Cotsoglou C, Pusceddu S, Giacomelli L, Ambrosi A, Sacco R. Facciorusso A, et al. Cancers (Basel). 2020 Dec 16;12(12):3796. doi: 10.3390/cancers12123796. Cancers (Basel). 2020. PMID: 33339274 Free PMC article. Review.
References
- J Gastroenterol Hepatol. 2009 Feb;24(2):223-7 - PubMed
- Am J Gastroenterol. 2012 Apr;107(4):569-77; quiz 578 - PubMed
- Liver Transpl. 2002 Oct;8(10):873-83 - PubMed
- J Vasc Interv Radiol. 2008 Jul;19(7):1087-92 - PubMed
- Eur Radiol. 2012 Sep;22(9):1983-90 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical